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Abstract
Background: The true interest of genetic immunisation might have been hastily underestimated based on overall
immunogenicity data in humans and lack of parallelism with other, more classical immunisation methods.
Principal Findings: Using malaria Liver Stage Antigen-3 (LSA-3), we report that genetic immunization induces in
chimpanzees, the closest relative of humans, immune responses which are as scarce as those reported using other DNA
vaccines in humans, but which nonetheless confer strong, sterile and reproducible protection. The pattern was consistent in
3/4 immunized apes against two high dose sporozoite challenges performed as late as 98 and 238 days post-immunization
and by a heterologous strain.
Conclusions: These results should, in our opinion, lead to a revisiting of the value of this unusual means of immunisation,
using as a model a disease, malaria, in which virulent challenges of volunteers are ethically acceptable.
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Introduction
At its advent, the use of genetic immunisation generated
considerable expectations. The initial enthusiasm was based on the
ease of production and purification of the immunogens as
compared to proteins, the simplicity of the approach and the
high immunogenicity in all animal models, including primates
employed at the pre-clinical level. This was followed by a period of
disillusionment and decreased interest, in particular from the
industrial sector, when it became clear that, for reasons that
remain poorly understood, the same high immunogenicity could
not be reproduced in humans. Genetic immunisation of volunteers
could induce at best CTL cells but low, or absent, CD4 T-cell and
antibody responses. The immunogenicity was so low that,
although reported, several clinical trials were considered unsuit-
able for publication. In many of these trials, challenge by the
infectious pathogens was either not possible or decided against in
view of the limited responses induced.
In the past, we have employed the chimpanzee as a model
system to study malaria because it is receptive to challenge by the
same species that infect humans, shares a very high degree of
homology with human beings (99.4%), has immune responses that
closely mimic those obtained in humans and can be immunolog-
ically investigated in nearly as much detail as mice and humans.
We have previously reported that protection could be obtained in
chimpanzees using Liver Stage Antigen-3, a new P. falciparum
protein identified by differential screening of immune responses
from protected and non-protected volunteers similarly immunized
with the irradiated parasite, which is expressed in sporozoite and
Liver stages [1]. In contrast to many other vaccine candidates, the
regions of immunological relevance are highly conserved.
Protection has been demonstrated in the chimpanzee, both by
lipopeptide immunization without adjuvant as well as by
recombinant protein immunization with an adjuvant acceptable
for human use, and in Aotus monkeys using non-adjuvated
particulate formulations [2].
Since the simplicity and ease of genetic immunization makes it a
valuable tool for the large scale Public Health problem posed by
malaria [3,4] we also wished to investigate the potential of LSA-3
presentation via naked DNA. The LSA-3 DNA vaccine, denoted
VR-LSA3, consisted of the pVR1020 plasmid into which a PCR-
amplified fragment coding for the largest part of the lsa-3 gene
from P. falciparum (the most hydrophobic C-terminal part was
deliberately deleted) was cloned in frame within the expression
cassette. We first exploited the homology between the P. falciparum
and P. yoelii LSA-3 antigens [5]. The P. falciparum LSA-3 construct
was used to demonstrate that genetic immunization of mice could
induce substantial protection against sporozoite challenge by the
heterologous species P. yoelii [5,6,7]. These results, together with
the strong protection obtained previously using sub-unit LSA-3
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studies in higher primates with P. falciparum LSA-3 in Vical vector.
Previous studies have shown that following P. falciparum sporozoite
challenges in the chimpanzee the reproducibility of blood
infections was remarkable [1] Although a limited number of
animals can be enrolled, the clear differences between vaccines
and controls, and the possibility to repeat challenges, provide
significant data. This was particularly well demonstrated in
animals undergoing five successive challenges [1].
Results and Discussion
Six adult chimpanzees were included in the study [8,9]: four
were injected three times at 4–5 week intervals with a one mg dose
of VR-LSA3, and two control animals were similarly immunized
with a control plasmid coding for a non-malaria related antigen,
the Respiratory Syncitial Virus protein. During and following the
immunization period, no adverse local or systemic reactions were
observed. A first challenge was performed 14 weeks after the third
immunization, by intravenous injection of 20,000 sporozoites from
the P. falciparum NF54 strain. In control animals, blood stage
parasites were detectable as soon as day six or seven post-
challenge, i.e. reflecting the first invasion of red blood cells by the
liver merozoites emerging from hepatic schizonts (Fig. 1). Three of
the four immunized animals were fully protected - no parasitized
red blood cells could be detected in samples taken daily during the
12 days survey period, which followed the challenge (Fig. 1). This
was established using three different methods: extensive micros-
copy, QBC and a sensitive PCR assay. In the fourth immunized
chimpanzee, Mayoumba, the course of parasitaemia was compa-
rable to that observed in controls.
Five months later, these six chimpanzees underwent a second
similar challenge by 20,000 P. falciparum sporozoites. Each animal
presented the same pattern as that observed following the first
challenge, a complete absence of parasites in the three previously
protected chimpanzees (Fig. 1) and a blood parasitaemia starting
on days six or seven in Mayoumba and in the two control animals.
Although the number of animals did not allow results to reach
statistical significance, they confirm the parasitological reproduc-
ibility of the model, since the status of protection or non-protection
was observed upon successive challenges, similarly to those 52
previous challenges reported elsewhere [1]. The consistency upon
successive challenges performed after a long delay has in fact
greater value than a statistically significant result on a single
challenge in a larger group. For instance, 5 consecutive challenges
performed over a year in chimpanzees immunized by either
optimally irradiated sporozoites or over-irradiated sporozoites,
provided in the first group consistent protection and in the second
group, consistent parasitemia with exactly the same pattern at
each challenge [1]. In contrast to mice, the chimpanzees being
rare and precious animals, only limited numbers can be studied
but the reproducibility of results upon successive challenges
provides in our opinion, greater confidence in the protection data
than larger groups of animals challenged once. In addition, if the
two challenges were cumulated, the difference of 0 protected out of
4 control challenged vs. 6 out of 8 protected in the immunized
group would become significant.
Although LSA-3 protein and peptides formulations have proved
able to induce strong antibody and cellular responses in lower as
well as higher primates [7,10,11,12] we could not detect any anti-
LSA-3 antibodies in the four chimpanzees immunized with LSA-3
DNA, either by ELISA using a large series of 21 peptides and 3
recombinant proteins, or by an immunofluorescence antibody
assay on P.falciparum sporozoite and Liver stages, throughout the
experiment i.e. including after challenge (data not shown). This
finding contrasts with results recorded in mice [6] but mimics the
results from genetic immunization of humans [13]. The high
antibody titers induced in lower primates and in rodents with both
the LSA-3 and CS DNA-constructs [6,14,15] further underline the
discrepancy with regard to genetic immunization between higher
primates and other animals.
The central role of interferon-gamma (IFN-c) in inhibiting liver
stage development has been repeatedly stressed under in vitro
[16,17] as well as in vivo conditions [1,2,18,19,20,21]. Our
immunization and challenges experiments in mice, Aotus monkeys
and Chimpanzees, all point to CD4 T-helper1 dependant IFN-c
secretion as the best surrogate of protection. In view of the large
number of T-cell epitopes identified within LSA-3, we therefore
focused our analysis of cellular responses towards 21 polypeptides
spanning the protein employing ELISpot-IFN-c assays. Positive
ELISpot responses were obtained in each of the four LSA-3
immunized chimpanzees (Fig. 2). These responses were specific as
negative results were recorded with the three negative controls,
and in control animals stimulated in vitro with LSA-3. Patterns
varied from one animal to the other, as expected for outbred
Figure 1. Blood parasitaemia profiles in the chimpanzees after
both sporozoite challenges. Names of control animals are italicized.
Names of protected LSA-3 immunized chimpanzees are underlined. All
results were confirmed by PCR and QBC analysis of the daily blood
samples.
doi:10.1371/journal.pone.0002659.g001
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specific anti-Class I blocking antibody as an indicator of CTL-type
responses [22]. Results, summarized in Figure 3, indicate a mixed
Class I and Class II type of response to selected peptides, with the
exception of GP15 where responses were almost entirely class I
dependent. In the non-protected immunized animal, Mayoumba,
T-cell responses were restricted to only peptide GP15, potentially
suggesting that responses to other regions of the molecule are
critical for protection. In contrast with results obtained in DNA-
immunized mice, no response to the R2 repeat region (recombi-
nant protein GST-NN and peptides RE, GP12-13-14) (Fig. 3) was
observed. Conversely, the results confirm the existence of T-cell
epitopes in the C-terminus unique sequences NR-B and NR-C
(Fig. 3) as observed previously in chimpanzees following
immunization with polypeptide formulations [1,6,7,10,12].
The chimpanzee is the primate most closely relative to humans,
and the suitability of this model for pre-erythrocytic vaccine
evaluation has already been discussed extensively earlier
[1,6,7,10,12]. In the absence of splenectomy the blood stage
infection is limited and self –resolving. In contrast the chimpanzee
is fully susceptible to sporozoite invasion and liver stages
development of P. falciparum in terms of numbers obtained and
intrahepatic maturation of schizonts, as much as are humans [23].
The short-term blood stage parasitemia is here used only a marker
of absence of blockade of the parasite at liver stage, it corresponds
to the first invasion of red cells by merozoites released from the
intrahepatocytic schizonts, followed by two cycles of intra-
erythrocytic schizogony. Moreover, chimpanzees, like humans
and in contrast to rodent models, are fully susceptible to successive
challenges by sporozoites, showing reproducible emergence of
blood stages on each challenge [1,6,7,10,12]. It is therefore fitted
to the assessment of pre-erythrocytic vaccines. LSA3 is only
expressed at sporozoite and liver stage, although leaky expression
in blood stages has been reported and can indeed be obtained
though only under artefactual conditions of cultivation at
laboratory level (Prieur E. et al in preparation).
In conclusion, the pre-clinical data presented here reinforces the
potential of DNA immunization in humans, which has previously
been questioned in view of the small number of immune effectors
elicited in this host [13,24] as compared to animal models
[3,4,6,25]. It also confirms the protective potential of the LSA-3
antigen [1].
The results indeed support the use of this delivery system,
despite the limited immune responses induced in the chimpanzee,
since these were nevertheless sufficient to induce sterile protection
in the closest living evolutionary relative to humans. It is
noteworthy that the types of immune response which were
induced by DNA in chimpanzees, i.e. specific cellular responses
but a lack of detectable B-cell responses, are reminiscent of those
observed in humans immunized by the same means either by a P.
falciparum CS-encoding construct expressed by the same vector
[13] or using genes from other pathogens such as hepatitis B, or
influenza (Sadoff, personal communication). Therefore, these
results demonstrate the immunological relevance of the chimpan-
zee to human beings for pre-clinical vaccine development [18,19].
In the CS study, the protective status of the volunteers was not
investigated in view of the scarcity of immune responses. Our
results suggest that even if restricted in number, the immune
responses, which were generated by LSA3, were efficient in
controlling malaria. A DNA plasmid encoding the PfLSA-3 full-
length, including an extreme 39 region encoding the C-terminus
very hydrophobic region, has been previously administered in a
Phase IIa trial as part of a DNA formulation comprising a mixture
of five genes, without success [26]. However the LSA3 construct
employed in this experiment had, in contrast to ours which
excluded the region coding for the extreme C-terminus, an
extremely low level of expression both in mice and in humans and
induced very scarce if any immune response in a very limited
number of volunteers. Therefore this experiment does not rule out
the potential of LSA3 genetic immunisation in humans.
Figure 2. Interferon-gamma ELISpot assays. Bars correspond to
the mean number of spot forming cells (SFC) per 10
6 cells from
triplicate wells, following stimulation by LSA-3 peptides (in gray),
negative controls (open bars) or positive control PPD (in black) (see
details in Mat. and Meth.). Results were considered as positive (dark
gray) when SFC were both .20 and .the highest mean SFCs of
negative controls plus two S.D. (not shown). Peptides that gave
negative results in all assays are not reported here.
doi:10.1371/journal.pone.0002659.g002
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immunological memory. In contrast with many other malaria
vaccination experiments, we deliberately performed two successive
sporozoite challenges and these only after a long delay following the
last immunization (3.5and 9 months). Our results demonstrated that
immunity induced by LSA-3 DNA vaccination persists for a long
duration without the necessity of an artificial boost [27,28].
These results are in keeping with previous reports showing
significant levels of protection in large mammals following DNA
vaccination against schistosoma, in the absence of a detectable
immune response [29]. This suggests that the true potential of
genetic immunisation might have been drastically underestimated
based on assessments of overall immunogenicity in humans using
vaccines against diseases where challenges are either hardly feasible
ornotcustomary(e.g.HIV,HBV,HCV,TB,Influenza).The lackof
parallelswithmoreclassicalimmunisationmethodsmightalsobethe
reason behind such hasty conclusions being made, despite the fact
that mechanisms of defence are in fact notoriously poorly
understood, or have yet to be identified, for numerous pathogens.
The situation is further complicated by circumstances where very
promisingdataisobtainedinmicefollowingDNAvaccination,while
in humans very poor immune responses with high inter-individual
variability are subsequently recorded [30].
Genetic immunisation is a very unusual means of immunisation
and it may therefore not be surprising that it can generate unusual
patterns of immune responses that differ from those obtained with
proteins or live vectors. For instance, DNA might preferentially
induce a subset of immune competent cells which are either poorly
characterized today, not detectable by current assays developed for
investigating other immunisation methods, or present in limited
numbers in peripheral blood samples. The results obtained in our
study using an antigen which has proved effective using more classical
antigen delivery systems in the same host, indicate that genetic
immunisation by LSA3 now deserves to be investigated in clinical
trials. Indeed, these findings suggest that the relative scarcity of an
immune response should not necessarily exclude the assessment of the
protective efficacy of a vaccine candidate when ethically feasible.
Materials and Methods
DNA construct
The LSA-3 plasmid vaccine, denoted as VR-LSA3, was
constructed by cloning a PCR fragment corresponding to almost
the entire lsa-3 gene of the P. falciparum clone 3D7, except for the
extreme 39 end encoding a highly hydrophobic region, as an in-frame
fusion with the human Tissue Plasminogen Activator leader sequence
Figure 3. LSA-3 DNA immunization induces specific IFN-c responses which are inhibited by an anti-MHC Class I blocking antibody.
Chimpanzee’s PBMC collected at week 30 were assayed for IFN-c production in an ELISPOT assay with recombinant proteins GST-729 and GST-PC or
peptide GP15, either in the absence (solid bars) or in the presence (open bars) of the HLA monomorphic monoclonal antibody W6/32 (Mat. and
Meth.). Results are expressed as the mean number of IFN-c SFCs per 1610
6 PBMC. The number of SFCs obtained with PBMC from the two negative
control chimpanzees was not significant (not shown).
doi:10.1371/journal.pone.0002659.g003
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the lsa-3 gene from reference strain K1 [1] and EMBL accession
number AJ007010), primers pVR20.59A (nucl. 432–460) and
pVR.39B (nucl. 5095–5064) amplify a 4663 bp fragment, whereas
in the vaccine VR-LSA3, the lsa-3 insert, which was amplified from
clone 3D7 DNA[31] and EMBL accessionnumber AE001424) using
these primers, spans over 3920 due to a shorter repeat region R2 in
3D7 compared to K1 parasites (data not shown). Following complete
sequence verification of the VR-LSA3 insert, large quantities of super
coiled plasmids were first prepared from a transformed E.coli DH5a
strain cultured in a 20 liter bioreactor under optimal conditions of
oxygenation and nutrition (in order to minimize the formation of
relaxed plasmid DNA), and further purified using EndoFree Plasmid
Giga Kits (Qiagen, Germany). The DNA solution was adjusted to
1 mg/ml using endotoxin-free PBS buffer, aliquoted in 1 ml samples
a n ds t o r e da t220uC. Endotoxin was present at concentrations
between 5 and 50 E.U./mg DNA, as determined with the Limulus
Amebocyte Lysate test (BioWhittaker, USA). Efficient expression of LSA-
3 by VR-LSA3 was verified: 1) through in vitro cultures of transfected
CHO cells (Lipofectamine, Gibco-BRL, USA) by immunofluores-
cence using anti-GST-729 and anti-GST-PC antibodies [1], directed
against the N- and C-terminal part of the antigen, respectively (data
not shown), 2) in vivo by intramuscular injections of the plasmid in
mice followed by immune response analysis [6]. Control plasmid
VR2402 was prepared in the same manner as plasmid VR-LSA3 and
consisted of the VR1020 vector expressing a non-relevant antigen,
the Respiratory Syncytial Virus protein (C. de Taisne, Aventis-
Pasteur, personal communication).
Animals and immunization
Six adult chimpanzees (Pan troglodytes) with no previous exposure
to malaria were included in the study.
Animals were handled in accordance with standard operating
procedures in the Centre International de Recherches Me ´dicales de
Franceville (CIRMF). The protocol of the present study was
discussed, revised and approved by the CIRMF Committee of
Ethic and Control of Animal Use Nu12, which include a physician,
three veterinaries specialized in primates, one being an ethologist, a
reknown primatologist, a scientist, a representative of the Ministry of
foreign affairs, and the Director of the CIRMF also a scientist.
For each animal, a 1 mg dose of the adequate plasmid
solubilized in 2 ml of endototoxin-free PBS was split and injected
intramuscularly in 2 symmetrical sites (tibialis anterior) each time
at weeks 0, 4 and 9.
Challenge and parasitemia follow-up
At weeks 24 and 49, all animals were challenged intravenously
with 20,000 sporozoites (NF54 strain, the parasite strain used for
challenge of human volunteers) obtained from dissected salivary
glands of infected female mosquitoes (Anopheles gambiae, the
mosquitoes species dominant in African settings) as previously
described, reared in Nijmegen under strict containment conditions
[32]. For protection assessment, blood samples were collected
daily from days 4 to 12 post-challenge and blood parasitaemias
were determined by extensive examination of Giemsa-stained
thick and thin film by experienced microscopists, by QBC and by
PCR as previously described [33,34]. Following the observation
period, all animals were curatively treated with chloroquine,
irrespective of their protective status.
Immune responses
Plasma antibody responses were measured by standard ELISA
and IFAT. For ELISA, coated antigens correspond to the LSA-3
recombinant proteins and synthetic peptides described below. IFAT
were performed on wet or dry NF54 sporozoites and day six post-
challenge liver stages from a chimpanzee as previously described [1].
T-cell responses were evaluated on PBLs. Forty ml of blood
were collected on heparin thirty weeks after the first immuniza-
tion. The number of IFN-c- producing cells was determined in
freshly Ficoll-isolated, unstimulated PBLs 40 hr after incubation
with the indicated antigens. Nitrocellulose-backed microtiter plates
(MAHAS45; Millipore Corp., Molsheim, France) were coated
with 50 mlo fa5mg/ml solution of an anti-human IFN-c capture
antibody (clone 350B10G6, Biosource International, California,
USA) diluted in carbonate buffer 50 mM, pH 9.6. After overnight
incubation at +4uC, the wells were washed three times with PBS,
and were incubated with PBS containing 5% human AB serum
(Institute Jacques Boy S.A., Reims, France). The plates were
washed again three times with PBS. PBL suspensions at
5610
5 cells/well in 200 ml RPMI 160 medium supplemented
with Penicillin-streptomycin, L-glutamine and Hepes (all pur-
chased from Gibco BRL, Life Technologies, Rockville, USA) and
with 10% human AB serum, together with 10 mg/ml of either
recombinant protein or synthetic peptide were introduced in each
well. In some assays, a 10 mg/ml solution of the blocking antibody
W6/32 (American Type Culture Collection, Rockville, MD) to a
monomorphic determinant from HLA class I molecules was
introduced in the wells. Plates were then incubated for 40 hr at
37uC in a humidified 5% CO2 air incubator. The plates were then
washed three times with PBS containing 0.05% Tween 20 (PBST),
and three times with PBS only. Wells were then overlaid with
50 ml of a solution of 2.5 mg/ml biotinylated anti-human IFN-c
detection antibody (clone 67F12A8, Biosource International,
California, USA) in PBS 3 hr at room temperature. Plates were
washed three times with PBS/T, and three times with PBS before
being treated with 50 ml/well of peroxydase-labelled streptavidin
(Boehringer Mannheim GmbH, Germany) at a dilution of 1/2000
in PBS. After one-hour incubation, plates were washed extensively
with PBS/T and PBS. Spots were revealed with the BCIP/NBT
reagent set (Promega, Madison Wi, USA) at sites where individual
cells had produced IFN-c. Results are expressed as the number of
spot forming cells (SFCs) per 10
6 PBL.
PBL were stimulated with: 1) LSA-3 recombinant proteins
GST-729, GST-NN and GST-PC, which have been previously
described [1] and were designed so as to cover 95% of the LSA-3
antigen; 2) The LSA-3 synthetic peptides previously reported in
ref. 17 and which are located in the K1 reference strain as follow:
GP2 (aa44-119), GP1 (aa100-222), GP14 (aa501-596), GP13
(aa646-706), GP12 (aa692-854), GP11 (aa840-907), GP10 (aa893-
999), GP9 (aa985-1040), GP8 (1026-1095), GP7 (aa1081-1157),
GP6 (aa1143-1255), GP5 (aa1241-1346), GP4 (aa1332-1517), GP3
(aa1503-1575) and GP15 (aa1601-1712); 3) Negative controls,
which correspond to the culture medium alone, the non-relevant
SALSA1 peptide [35] or the glutathion-S-transferase from
Schistosoma mansoni expressed from the pGEX vector (Invitrogen,
The Netherlands); 4) the positive control Purified Protein
Derivative (PPD).
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